MCID: OVR114
MIFTS: 54

Ovarian Cancer 1

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 53 28
Ovarian Carcinoma 12 14 69
Ovarian Cancer, Susceptibility to 53 13
Ovarian Cancer, Susceptibility to, 1 53
Malignant Neoplasm of Ovary 69
Ovarian Epithelial Cancer 41
Epithelial Ovarian Cancer 69
Ovarian Cancer 53
Ovcas1 53

Classifications:



External Ids:

OMIM 53 607893
Disease Ontology 12 DOID:4001
MeSH 41 C538090
NCIt 46 C4908

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian carcinoma, is related to brca1 hereditary breast and ovarian cancer syndrome and ovarian cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are TGF-Beta Pathway and Endometrial cancer. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include lung, ovary and cervix, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Description from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 brca1 hereditary breast and ovarian cancer syndrome 32.7 BRCA1 BRCA2
2 ovarian cancer 31.6 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
3 ovarian epithelial cancer 12.3
4 hereditary site-specific ovarian cancer syndrome 10.8 BRCA1 BRCA2
5 tuberculous salpingitis 10.8 BRCA1 BRCA2 ERBB2
6 synchronous bilateral breast carcinoma 10.8 BRCA1 BRCA2 TP53
7 breast reconstruction 10.8 BRCA1 BRCA2
8 nosophobia 10.8 BRCA1 BRCA2
9 cancerophobia 10.8 BRCA1 BRCA2
10 uterine body mixed cancer 10.8 ARID1A ERBB2 TP53
11 papillary serous adenocarcinoma 10.8 BRCA1 KRT7 TP53
12 mucoepidermoid esophageal carcinoma 10.7 CEACAM5 TP53
13 mutagen sensitivity 10.7 BRCA1 BRCA2 TP53
14 bilateral breast cancer 10.7 BRCA1 BRCA2 ERBB2
15 lobular neoplasia 10.7 BRCA1 CDH1 ERBB2
16 cystadenofibroma 10.7 BRCA1 BRCA2 KRT7
17 vulvar intraepithelial neoplasia 10.7 KRT7 MMP2 TP53
18 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.7 ARID1A PIK3CA TP53
19 hereditary breast ovarian cancer syndrome 10.7 BRCA1 BRCA2 TP53
20 ovarian clear cell adenocarcinoma 10.7 ARID1A HNF1B PIK3CA
21 mixed cell type cancer 10.7 ERBB2 KRT7 TP53
22 gallbladder squamous cell carcinoma 10.7 CEACAM5 ERBB2
23 uterine carcinosarcoma 10.7 ERBB2 PIK3CA TP53
24 granulosa cell tumor of the ovary 10.7 ERBB2 KRT7 TP53
25 female breast cancer 10.7 BRCA2 ERBB2 TP53
26 hidradenocarcinoma 10.7 ERBB2 KRT7 TP53
27 uterine corpus serous adenocarcinoma 10.7 BRCA1 BRCA2 ERBB2 TP53
28 fallopian tube adenocarcinoma 10.7 BRCA1 BRCA2 ERBB2 TP53
29 acinar cell carcinoma 10.7 BRCA2 KRT7 TP53
30 microcystic meningioma 10.7 CDH1 MMP2 VEGFA
31 vulval paget's disease 10.7 CEACAM5 ERBB2 KRT7
32 cutaneous mucoepidermoid carcinoma 10.7 CEACAM5 KRT7
33 breast squamous cell carcinoma 10.7 CDH1 CEACAM5 ERBB2
34 breast cystic hypersecretory carcinoma 10.7 CDH1 ERBB2
35 vulva adenocarcinoma 10.7 CEACAM5 ERBB2 KRT7
36 pancreatic serous cystadenoma 10.7 CEACAM5 KRT7 VEGFA
37 anal gland adenocarcinoma 10.7 CEACAM5 KRT7
38 sporadic breast cancer 10.7 BRCA1 BRCA2 ERBB2 TP53
39 signet ring cell adenocarcinoma 10.7 CDH1 KRT7 TP53
40 adult hepatocellular carcinoma 10.7 PIK3CA TP53
41 biliary papillomatosis 10.7 CEACAM5 KRT7 TP53
42 glycogen-rich clear cell breast carcinoma 10.7 BRCA1 BRCA2 KRT7 TP53
43 sweat gland cancer 10.7 ERBB2 KRT7 TP53
44 pancreatic ductal carcinoma 10.7 KRT7 TP53 VEGFA
45 breast-ovarian cancer, familial 1 10.7 BRCA1 BRCA2
46 serous cystadenocarcinoma 10.7 MMP2 TP53 VEGFA
47 in situ carcinoma 10.7 BRCA1 CDH1 ERBB2 TP53
48 intracranial chondrosarcoma 10.7 CEACAM5 TP53
49 infiltrative basal cell carcinoma 10.7 CDH1 CEACAM5 KRT7
50 grade iii astrocytoma 10.7 MMP2 TP53 VEGFA

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 BRCA1 BRCA2 CDH1 ERBB2 HNF1B KRT7

MGI Mouse Phenotypes related to Ovarian Cancer 1:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
2 homeostasis/metabolism MP:0005376 10.25 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
3 endocrine/exocrine gland MP:0005379 10.23 CDH1 ERBB2 HNF1B PHF13 PIK3CA TP53
4 growth/size/body region MP:0005378 10.21 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
5 embryo MP:0005380 10.18 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
6 mortality/aging MP:0010768 10.13 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
7 digestive/alimentary MP:0005381 10.1 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
8 integument MP:0010771 10.02 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
9 muscle MP:0005369 9.86 PIK3CA TP53 VEGFA ARID1A BRCA1 ERBB2
10 neoplasm MP:0002006 9.85 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
11 reproductive system MP:0005389 9.7 ACSBG1 AREG ARID1A BRCA1 BRCA2 CDH1
12 skeleton MP:0005390 9.28 BRCA1 BRCA2 DPH1 ERBB2 ARID1A MMP2

Drugs & Therapeutics for Ovarian Cancer 1

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
CEA-Scan 17 Immunomedics April 1996
2
Doxil 17 45 DOXORUBICIN HYDROCHLORIDE Alza June 1999
3
Ethyol 17 AMIFOSTINE Alza December 8, 1995
4
Hycamtin 17 45 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
5
Iressa 17 45 GEFITINIB AstraZeneca May 2003
6
Lynparza 17 45 OLAPARIB AstraZeneca December 2014

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 639)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
3
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
4
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
9
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
10
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
11
Peppermint Approved, Nutraceutical Phase 4
12
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 54670067 5785
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 68-26-8, 11103-57-4 445354
14
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
15
Substance P Investigational Phase 4,Phase 2,Not Applicable 33507-63-0 44359816
16 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Ferrous fumarate Phase 4,Not Applicable,Early Phase 1
36 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antifibrinolytic Agents Phase 4
45 Coagulants Phase 4,Phase 2,Not Applicable
46 Hemostatics Phase 4,Phase 2,Not Applicable
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 neurokinin A Phase 4,Phase 2,Not Applicable
50 Neurokinin-1 Receptor Antagonists Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2303)

# Name Status NCT ID Phase Drugs
1 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
2 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
3 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
6 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
7 Guilford Genomic Medicine Initiative (GGMI) Completed NCT01372553 Phase 4
8 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
9 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
10 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
11 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
12 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
13 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
14 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
15 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Recruiting NCT01953107 Phase 4
16 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
17 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
18 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
19 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
20 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
21 Lymphadenectomy In Ovarian Neoplasms Unknown status NCT00712218 Phase 3
22 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
23 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
24 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
25 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
26 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
27 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
28 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
29 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
30 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
31 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
32 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
33 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
34 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
35 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
36 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
37 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed NCT01847274 Phase 3 Active comparator: Niraparib;placebo
38 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
39 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer Completed NCT00102375 Phase 3 Topotecan
40 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer Completed NCT00102414 Phase 3 Gemcitabine
41 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer Completed NCT00003695 Phase 3 chemotherapy
42 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
43 Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
44 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy Completed NCT00312988 Phase 3 Hycamtin;Gemcitabine
45 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
46 Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer Completed NCT00426257 Phase 3
47 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
48 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
49 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
50 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed NCT00113607 Phase 3 Trabectedin;DOXIL;Dexamethasone

Search NIH Clinical Center for Ovarian Cancer 1

Cochrane evidence based reviews: ovarian epithelial cancer

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 28

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

38
Lung, Ovary, Cervix, Testes

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 1761)
# Title Authors Year
1
Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. ( 29423077 )
2018
2
TLR4 and NFI_B signaling is critical for taxol resistance in ovarian carcinoma cells. ( 28771725 )
2018
3
The role of the long non-coding RNA TDRG1 in epithelial ovarian carcinoma tumorigenesis and progression through miR-93/RhoC pathway. ( 28984384 )
2018
4
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
5
Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. ( 28646019 )
2017
6
Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. ( 27913862 )
2017
7
The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma. ( 29022892 )
2017
8
Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma. ( 28668894 )
2017
9
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection. ( 27362900 )
2017
10
Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma. ( 27443420 )
2017
11
Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: A case report. ( 28796031 )
2017
12
The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma. ( 28428108 )
2017
13
The role of miR-372 in ovarian carcinoma cell proliferation. ( 28456593 )
2017
14
ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells. ( 28184931 )
2017
15
CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma. ( 28346425 )
2017
16
Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression. ( 28259910 )
2017
17
Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor I+ in high-grade serous ovarian carcinoma. ( 28414091 )
2017
18
The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression. ( 28864116 )
2017
19
Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma. ( 27941884 )
2017
20
Glycerol-3-phosphate Acyltransferase 1 Promotes Tumor Cell Migration and Poor Survival in Ovarian Carcinoma. ( 28652252 )
2017
21
Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy. ( 28160193 )
2017
22
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. ( 28646021 )
2017
23
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. ( 28065619 )
2017
24
Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway. ( 28651497 )
2017
25
Struma Ovarii with Pseudo-Meigs' Syndrome and Raised Cancer Antigen-125 Levels Masquerading as an Ovarian Carcinoma Case report and literature review. ( 28690899 )
2017
26
BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. ( 27899818 )
2016
27
DEF6 expression in ovarian carcinoma correlates with poor patient survival. ( 27488395 )
2016
28
Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. ( 26716408 )
2016
29
miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. ( 26675258 )
2016
30
Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma. ( 27748916 )
2016
31
Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma. ( 26825003 )
2016
32
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. ( 27209210 )
2016
33
Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro. ( 27211906 )
2016
34
MAP3K3 overexpression is associated with poor survival in ovarian carcinoma. ( 26997451 )
2016
35
Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma. ( 26512788 )
2016
36
The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma. ( 26820075 )
2016
37
miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma. ( 26563371 )
2016
38
Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma. ( 28189149 )
2016
39
Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways. ( 26648098 )
2016
40
miR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R. ( 26695144 )
2016
41
Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. ( 27216459 )
2016
42
Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. ( 26482613 )
2016
43
The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas. ( 26250458 )
2016
44
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. ( 26847329 )
2016
45
Inhibition of Notch 1 receptor influenced the differentiation of Lin-CD45RA-dendritic cell precursors within ovarian carcinoma microenvironment. ( 27259477 )
2016
46
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. ( 26748848 )
2016
47
Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma. ( 27127000 )
2016
48
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma. ( 27622508 )
2016
49
Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma. ( 26615423 )
2016
50
Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement. ( 27271776 )
2016

Variations for Ovarian Cancer 1

ClinVar genetic disease variations for Ovarian Cancer 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
2 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
3 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
4 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
5 BRCA1 NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter) single nucleotide variant Pathogenic rs80356898 GRCh37 Chromosome 17, 41245861: 41245861
6 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh37 Chromosome 13, 32914174: 32914174
7 BRCA2 NM_000059.3(BRCA2): c.7806-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs81002836 GRCh37 Chromosome 13, 32936658: 32936658
8 BRCA1 NM_007294.3(BRCA1): c.3375_3376delTC (p.Pro1126Ilefs) deletion Pathogenic rs80357828 GRCh37 Chromosome 17, 41244172: 41244173
9 BRCA1 NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp) single nucleotide variant Pathogenic rs55770810 GRCh37 Chromosome 17, 41215948: 41215948

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

Pathways related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 AREG BRCA1 CDH1 ERBB2 HNF1B PIK3CA
2
Show member pathways
12.9 BRCA1 BRCA2 CDH1 ERBB2 PIK3CA TP53
3 12.59 BRCA2 CDH1 ERBB2 MMP2 PIK3CA TP53
4
Show member pathways
12.49 ERBB2 MMP2 PIK3CA TP53 VEGFA
5 12.41 BRCA1 ERBB2 PIK3CA TP53 VEGFA
6
Show member pathways
12.37 AREG ERBB2 PIK3CA TP53 VEGFA
7
Show member pathways
12.37 ARID1A BRCA1 BRCA2 CDH1 ERBB2 PIK3CA
8
Show member pathways
12.34 AREG CDH1 ERBB2 PIK3CA TP53
9 12.14 ERBB2 MMP2 PIK3CA TP53 VEGFA
10 12.09 CDH1 MMP2 TP53 VEGFA
11 11.99 MMP2 PIK3CA TP53 VEGFA
12 11.98 MMP2 PSMA2 TP53 VEGFA
13 11.95 BRCA1 BRCA2 CDH1 TP53 VEGFA
14
Show member pathways
11.84 BRCA2 ERBB2 PIK3CA TP53 VEGFA
15
Show member pathways
11.7 BRCA1 BRCA2 TP53
16 11.59 ERBB2 PIK3CA TP53
17 11.57 BRCA1 ERBB2 PIK3CA TP53
18
Show member pathways
11.5 AREG ERBB2 MMP2 PIK3CA
19 11.47 BRCA1 TP53 VEGFA
20 11.22 CDH1 ERBB2 MMP2 TP53 VEGFA
21 11.16 CDH1 ERBB2 PIK3CA
22 10.84 ARID1A BRCA1 ERBB2 PIK3CA TP53

GO Terms for Ovarian Cancer 1

Cellular components related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 ACSBG1 AREG BRCA1 BRCA2 CDH1 DPH1

Biological processes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 BRCA1 ERBB2 HNF1B TP53 VEGFA
2 cell proliferation GO:0008283 9.72 AREG BRCA2 DPH1 ERBB2 TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.63 ARID1A BRCA1 BRCA2 CDH1 HNF1B TP53
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 AREG TP53 VEGFA
5 cellular response to indole-3-methanol GO:0071681 9.26 BRCA1 CDH1
6 chordate embryonic development GO:0043009 8.96 BRCA1 BRCA2
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....